Efficacy and Safety of Combined Pharmacotherapies in Moderate‐to‐Severe Allergic Rhinitis: A Network Meta‐Analysis
International Forum of Allergy & Rhinology · 2025
DOI: 10.1002/alr.23578 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von Yuan Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Anti-Allergic Agents, Histamine Antagonists, Leukotriene Antagonists, Rhinitis, Allergic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 80 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Beijing Municipal Science and Technology Commission.
Abstract (Originalsprache)
Background
Combination pharmacotherapies are often selected for moderate‐to‐severe allergic rhinitis (AR), particularly when monotherapies do not control symptoms effectively. However, few studies have compared the efficacy and safety of different combination regimens. Therefore, we performed this study to investigate the clinical benefits of different combination strategies for moderate‐to‐severe AR.
Methods
Electronic databases were searched (inception‐May 31, 2024) for randomized controlled trials involving combination therapies for treating moderate‐to‐severe AR. The medication classes included intranasal corticosteroids (INCS), intranasal antihistamines (INAH), oral antihistamines (OAH), and oral leukotriene receptor antagonists (LTRA). A network meta‐analysis with a random‐effects model was performed following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses guidelines.
Results
Forty‐eight eligible studies with 17,188 participants were included. In this meta‐analysis, INAH and INCS, OAH and INCS, and INCS were the most effective in improving Total Nasal Symptom Score, and INAH and INCS, INAH, and INCS most effectively enhanced the total ocular symptom score. INCS and LTRA, OAH and INCS, and INAH and INCS showed the greatest benefit in improving the Rhinitis Quality of Life Questionnaire. Although INCS and INAH and INAH increased the risk of overall adverse events, specific adverse events predominantly included a bitter taste.
Conclusion
Combination therapies demonstrated superior efficacy compared to monotherapies overall. The INAH and INCS combination provided the greatest advantage in symptom improvement. The combination of OAH and INCS could be a viable alternative treatment option if the bitter taste is unacceptable. Our findings provide novel insights into optimizing personalized combination therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
- Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing, China.
ORCID-Profile: Yuan Zhang, Zengxiao Zhang, Luo Zhang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Beijing Municipal Science and Technology Commission
- The program for the Changjiang scholars and innovative research team
- Beijing Hospitals Authority Clinical medicine Development of special funding
Zitieren
APA
Zhang, Y., Zhang, Z., Wang, C., & Zhang, L. (2025). Efficacy and Safety of Combined Pharmacotherapies in Moderate‐to‐Severe Allergic Rhinitis: A Network Meta‐Analysis. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23578
Vancouver
Zhang Y, Zhang Z, Wang C, Zhang L. Efficacy and Safety of Combined Pharmacotherapies in Moderate‐to‐Severe Allergic Rhinitis: A Network Meta‐Analysis. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23578
BibTeX
@article{Zhang2025,
author = {Zhang, Yuan and Zhang, Zengxiao and Wang, Chengshuo and Zhang, Luo},
title = {Efficacy and Safety of Combined Pharmacotherapies in Moderate‐to‐Severe Allergic Rhinitis: A Network Meta‐Analysis},
journal = {International Forum of Allergy & Rhinology},
year = {2025},
doi = {10.1002/alr.23578}
}
EUVIMED